Literature DB >> 22699442

Bacillus subtilis: a temperature resistant and needle free delivery system of immunogens.

Hellen Amuguni1, Saul Tzipori.   

Abstract

Most pathogens enter the body through mucosal surfaces. Mucosal immunization, a non-invasive needle-free route, often stimulates a mucosal immune response that is both effective against mucosal and systemic pathogens. The development of mucosally administered heat-stable vaccines with long shelf life would therefore significantly enhance immunization programs in developing countries by avoiding the need for a cold chain or systemic injections. Currently, recombinant vaccine carriers are being used for antigen delivery. Engineering Bacillus subtilis for use as a non-invasive and heat stable antigen delivery system has proven successful. Bacterial spores protected by multiple layers of protein are known to be robust and resistant to desiccation. Stable constructs have been created by integration into the bacterial chromosome of immunogens. The spore coat has been used as a vehicle for heterologous antigen presentation and protective immunization. Sublingual (SL) and intranasal (IN) routes have recently received attention as delivery routes for therapeutic drugs and vaccines and recent attempts by several investigators, including our group, to develop vaccines that can be delivered intranasally and sublingually have met with a lot of success. As discussed in this review, the use of Bacillus subtilis to express antigens that can be administered either intranasally or sublingually is providing new insights in the area of mucosal vaccines. In our work, we evaluated the efficacy of SL and IN immunizations with B. subtilis engineered to express tetanus toxin fragment C (TTFC) in mice and piglets. These bacteria engineered to express heterologous antigen either on the spore surface or within the vegetative cell have been used for oral, IN and SL delivery of antigens. A Bacillus subtilis spore coat protein, CotC was used as a fusion partner to express the tetanus fragment C. B. subtilis spores known to be highly stable and safe are also easy to purify making this spore-based display system a potentially powerful approach for surface expression of antigens. These advances will help to accelerate the development and testing of new mucosal vaccines against many human and animal diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699442      PMCID: PMC3495728          DOI: 10.4161/hv.20694

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  72 in total

Review 1.  Recent developments in adjuvants for vaccines against infectious diseases.

Authors:  D T O'Hagan; M L MacKichan; M Singh
Journal:  Biomol Eng       Date:  2001-10-15

2.  Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.

Authors:  A Rudin; G C Riise; J Holmgren
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

3.  Bacterial spores as vaccine vehicles.

Authors:  Le H Duc; Huynh A Hong; Neil Fairweather; Ezio Ricca; Simon M Cutting
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

4.  Sublingual immunization induces broad-based systemic and mucosal immune responses in mice.

Authors:  Nicolas Cuburu; Mi-Na Kweon; Joo-Hye Song; Catherine Hervouet; Carmelo Luci; Jia-Bin Sun; Paul Hofman; Jan Holmgren; Fabienne Anjuère; Cecil Czerkinsky
Journal:  Vaccine       Date:  2007-10-25       Impact factor: 3.641

5.  Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system.

Authors:  Franck Lemiale; Wing-pui Kong; Levent M Akyürek; Xu Ling; Yue Huang; Bimal K Chakrabarti; Michael Eckhaus; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Molecular characterization and identification of Bacillus clausii Strains marketed for use in oral bacteriotherapy.

Authors:  S Senesi; F Celandroni; A Tavanti; E Ghelardi
Journal:  Appl Environ Microbiol       Date:  2001-02       Impact factor: 4.792

7.  Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C.

Authors:  Sangun Lee; Boris R Belitsky; David W Brown; James P Brinker; Kathryn O Kerstein; John E Herrmann; Gerald T Keusch; Abraham L Sonenshein; Saul Tzipori
Journal:  Vaccine       Date:  2010-08-13       Impact factor: 3.641

8.  The structures of the H(C) fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding.

Authors:  P Emsley; C Fotinou; I Black; N F Fairweather; I G Charles; C Watts; E Hewitt; N W Isaacs
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

9.  Bacillus probiotics: spore germination in the gastrointestinal tract.

Authors:  Gabriella Casula; Simon M Cutting
Journal:  Appl Environ Microbiol       Date:  2002-05       Impact factor: 4.792

10.  Characterization of two Bacillus probiotics.

Authors:  D H Green; P R Wakeley; A Page; A Barnes; L Baccigalupi; E Ricca; S M Cutting
Journal:  Appl Environ Microbiol       Date:  1999-09       Impact factor: 4.792

View more
  28 in total

1.  Oral delivery of Bacillus subtilis spore expressing enolase of Clonorchis sinensis in rat model: induce systemic and local mucosal immune responses and has no side effect on liver function.

Authors:  Jinyun Yu; Tingjin Chen; Zhizhi Xie; Pei Liang; Honglin Qu; Mei Shang; Qiang Mao; Dan Ning; Zeli Tang; Mengchen Shi; Lina Zhou; Yan Huang; Xinbing Yu
Journal:  Parasitol Res       Date:  2015-04-17       Impact factor: 2.289

Review 2.  Impact of culture condition modulation on the high-yield, high-specificity and cost-effective production of terpenoids from microbial sources: A review.

Authors:  Vibha Shukla; Suresh Chandra Phulara
Journal:  Appl Environ Microbiol       Date:  2020-11-30       Impact factor: 4.792

3.  Comparative analysis of immune effects in mice model: Clonorchis sinensis cysteine protease generated from recombinant Escherichia coli and Bacillus subtilis spores.

Authors:  Zhanshuai Wu; Zeli Tang; Mei Shang; Lu Zhao; Lina Zhou; Xiangzhan Kong; Zhipeng Lin; Hengchang Sun; Tingjin Chen; Jin Xu; Xuerong Li; Yan Huang; Xinbing Yu
Journal:  Parasitol Res       Date:  2017-05-13       Impact factor: 2.289

4.  Oral Application of Recombinant Bacillus subtilis Spores to Dogs Results in a Humoral Response against Specific Echinococcus granulosus Paramyosin and Tropomyosin Antigens.

Authors:  Cédric M Vogt; Maria Teresa Armúa-Fernández; Kurt Tobler; Monika Hilbe; Claudio Aguilar; Mathias Ackermann; Peter Deplazes; Catherine Eichwald
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

5.  The storage stability of Bacillus subtilis spore displaying cysteine protease of Clonorchis sinensis and its effect on improving the gut microbiota of mice.

Authors:  Zeli Tang; Zhanshuai Wu; Hengchang Sun; Lu Zhao; Mei Shang; Mengchen Shi; Hongye Jiang; Zhipeng Lin; Xinyi Zhou; Xuerong Li; Xinbing Yu; Yan Huang
Journal:  Appl Microbiol Biotechnol       Date:  2021-02-19       Impact factor: 4.813

6.  Membrane Proteomes and Ion Transporters in Bacillus anthracis and Bacillus subtilis Dormant and Germinating Spores.

Authors:  Yan Chen; Bidisha Barat; W Keith Ray; Richard F Helm; Stephen B Melville; David L Popham
Journal:  J Bacteriol       Date:  2019-02-25       Impact factor: 3.490

7.  Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine.

Authors:  Guangyu Zhao; Yu Miao; Yan Guo; Hongjie Qiu; Shihui Sun; Zhihua Kou; Hong Yu; Junfeng Li; Yue Chen; Shibo Jiang; Lanying Du; Yusen Zhou
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Comparative analysis of Bacillus subtilis spores and monophosphoryl lipid A as adjuvants of protein-based mycobacterium tuberculosis-based vaccines: partial requirement for interleukin-17a for induction of protective immunity.

Authors:  Sandra C Esparza-Gonzalez; Amber R Troy; Angelo A Izzo
Journal:  Clin Vaccine Immunol       Date:  2014-01-29

Review 9.  Exploitation of Bacillus subtilis as a robust workhorse for production of heterologous proteins and beyond.

Authors:  Wenjing Cui; Laichuang Han; Feiya Suo; Zhongmei Liu; Li Zhou; Zhemin Zhou
Journal:  World J Microbiol Biotechnol       Date:  2018-09-10       Impact factor: 3.312

Review 10.  Current and novel approaches to vaccine development against tuberculosis.

Authors:  Mark J Cayabyab; Lilia Macovei; Antonio Campos-Neto
Journal:  Front Cell Infect Microbiol       Date:  2012-12-06       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.